Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab

Baron, Jennifer A.

doi:10.1016/j.jdcr.2017.02.016

Cited by 22 publications

(33 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, clinical experiences suggesting that secukinumab could become a treatment choice for EP, especially in patients that have had unsuccessful previous therapies even with biologics, have been published (14)(15)(16)(17). Balestri et al reported that addon therapy with secukinumab in a patient with unsatisfactorily controlled acrodermatitis continua of Hallopeau provided sustained improvement, confirming similar experiences (18,19). The authors had chosen this drug based on previously published reports both in patients with plaque psoriasis and with pustular diseases (20,21), and because of a convenient schedule that favored adherence.…”

Section: Secukinumab Treatment In Psoriatic Patients: Italian Experiementioning

confidence: 72%

Secukinumab treatment in psoriatic patients: Italian experiences

Idolazzi

2018

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Section: Secukinumab Treatment In Psoriatic Patients: Italian Experiementioning

confidence: 72%

Secukinumab treatment in psoriatic patients: Italian experiences

Idolazzi

2018

Journal of Dermatological Treatment

View full text Add to dashboard Cite

“…A total of 20 articles (86 patients) reported the use of “next generation biologics” for the treatment of pustular psoriasis. Eight case reports, eight case series, and two observational studies were reviewed (Table ). When reported (81 cases), mean age at presentation was 50.6 (range: 35–72 years), and 33 of 86 (38.3%) patients were male (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…An increased expression of IL‐17A has been consistently observed in patients with GPP, making it an important target . Most patients achieved favorable outcomes with a prompt onset of response of 2–5 days and clearance obtained by the third week . Most common AE were infections, allergic reactions, and injection site reactions .…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Biological therapy for pustular psoriasis: a systematic review

et al. 2019

View full text Add to dashboard Cite

Background The anecdotic evidence of the benefits from biologic agents for psoriasis is extensive. However, data on the efficacy of biologic agents for pustular psoriasis are limited.Methods To update the data on the efficacy and safety of biologic agents for the management of pustular psoriasis. A systematic review of published data regarding biologic therapies on PubMED database, used in the management of pustular psoriasis from 2012 was undertaken.Results A total of 209 articles were identified, and 43 articles were selected for inclusion. TNF-a inhibitors were used in 205 patients, and 86 patients received ustekinumab, secukinumab, brodalumab, ixekizumab and IL-1 inhibitors. Overall response was favorable for most modalities. No serious adverse events were reported. Inconsistent measures of treatment response and study variability limited the overall evaluation of data. Conclusions Infliximab and ustekinumab have the most evidence of efficacy and safety for the treatment of pustular psoriasis. Recent evidence supports the use of IL-17 antagonists. Prospective controlled and comparative trials are needed to further explore the efficacy and safety of biologic agents in order to establish objective recommendations for the management of this challenging condition. mia, hypocalcemia, elevated erythrocyte sedimentation rate, C-reactive protein, antistreptolysin O antibody levels, and/or IgG or IgA. 7Although most cases of pustular psoriasis are believed to be idiopathic, there are several factors that can trigger disease such as pregnancy, infections, contact to allergens, drugs, and withdrawal from medications used for psoriasis, including steroids, methotrexate, and cyclosporine. 9-11 Paradoxically, the use of tumor necrosis factor (TNF)-a inhibitors may also precipitate pustular psoriasis. 12,13 Pustular psoriasis is a challenging condition to treat, and evidence regarding management strategies is limited. The National Psoriasis Foundation's (NPF) most recent guidelines of care for pustular psoriasis were published in 2012. 14 Recognizing that the "overall quality of the literature about the treatment of pustular psoriasis is weak," the group recommended acitretin, cyclosporine, methotrexate, and infliximab as first-line treatment options for adult GPP. In 2014, Levin et al. 15 suggested an algorithm for biologic treatments of GPP, recommending infliximab as first-line therapy for patients with acute, severe GPP.These recommendations are not universally accepted and have not been updated to include recently introduced biologic agents such as IL-17 inhibitors. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]

show abstract

“…Darüber hinaus wurden in einer Untergruppe von ACS-Patienten Mutationen in einem Gen nachgewiesen, das für den mit der Psoriasis pustulosa generalisata assoziierten IL-36-Rezeptor-Antagonisten (IL36RN) kodiert, ein Befund, der Gemeinsamkeiten mit anderen Formen der pustulösen Psoriasis nahelegt [4,5]. Kürzlich wurde über eine deutliche Verbesserung der ACS bei drei Patienten berichtet, die mit IL-17A Blockern (zwei Fälle mit Secukinumab [2,3], ein Fall mit Ixekizumab [1]) behandelt wurden. Passend dazu war der Nachweis einer erhöhten intraläsionalen IL-17-Expression bei den beiden Patienten, bei denen eine Analyse durchgeführt worden war [1,3].…”

Section: Diskussionunclassified